These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1902881)

  • 1. Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.
    Mehltretter G; Heinz S; Schopohl J; von Werder K; Müller OA
    Klin Wochenschr; 1991 Jan; 69(2):83-90. PubMed ID: 1902881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
    Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
    Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
    Fredstorp L; Kutz K; Werner S
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
    Wang C; Lam KS; Arceo E; Chan FL
    J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
    Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
    McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
    Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
    Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
    Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
    J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Men with acromegaly need higher doses of octreotide than women.
    Edén Engström B; Burman P; Karlsson FA
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):73-7. PubMed ID: 11849249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF; Harris AG; Zhu XF; Deng JY
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995.
    Ducasse MC; Tauber JP; Tourre A; Bonafe A; Babin T; Tauber MT; Harris AG; Bayard F
    J Clin Endocrinol Metab; 1987 Nov; 65(5):1042-6. PubMed ID: 2889748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.